2007
DOI: 10.1016/j.amjhyper.2006.08.002
|View full text |Cite
|
Sign up to set email alerts
|

Effect of PPAR-γ Agonist on Adiponectin Levels in the Metabolic Syndrome: Lessons From the High Fructose Fed Rat Model

Abstract: This study shows for the first time that in an animal model of MS, the insulin sensitizer, rosiglitazone, improves the metabolic profile and increases plasma levels of adiponectin and its gene expression. It is possible therefore that rosiglitazone exerts its beneficial effects by increasing the levels of adiponectin.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

7
47
0
9

Year Published

2008
2008
2019
2019

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 87 publications
(63 citation statements)
references
References 30 publications
7
47
0
9
Order By: Relevance
“…However, telmisartan did not affect plasma adiponectin, a protein whose levels are known to increase with existing PPARγ agonists and to correlate with insulin sensitivity (23)(24)(25)(26). We recently showed in fructose fed rats that the PPARγ agonist rosiglitazone improved the metabolic profile to a degree similar to telmisartan, but with increases in plasma adiponectin levels and gene expression (15). Therefore, it is unlikely that adiponectin mediates telmisartan's beneficial effect on metabolic parameters.…”
Section: Discussionmentioning
confidence: 96%
See 1 more Smart Citation
“…However, telmisartan did not affect plasma adiponectin, a protein whose levels are known to increase with existing PPARγ agonists and to correlate with insulin sensitivity (23)(24)(25)(26). We recently showed in fructose fed rats that the PPARγ agonist rosiglitazone improved the metabolic profile to a degree similar to telmisartan, but with increases in plasma adiponectin levels and gene expression (15). Therefore, it is unlikely that adiponectin mediates telmisartan's beneficial effect on metabolic parameters.…”
Section: Discussionmentioning
confidence: 96%
“…Accumulating data have shown that PPARγ activation increases adiponectin levels (14,15). Recent studies suggested that telmisartan, an angiotensin II receptor antagonist, is also a partial PPARγ agonist (16,17).…”
Section: Discussionmentioning
confidence: 99%
“…15 To determine the role of Treg in the metabolic syndrome, vascular oxidative stress and inflammation and the number and function of Treg were studied in high-fructose diet-fed SpragueDawley rats, a well-established model mimicking some features of the western diet-induced metabolic syndrome. 16,17 These rats exhibit hypertension, insulin resistance, and abnormal lipid profile resembling the human metabolic syndrome better than a monogenic model. We hypothesized that vascular oxidative stress and inflammation and changes in the immune response, including Treg activity and response, participate in the mechanisms leading to the metabolic syndrome.…”
Section: Foxp3mentioning
confidence: 99%
“…16,17 These rats exhibit hypertension, insulin resistance, and abnormal lipid profile resembling the human metabolic syndrome better than a monogenic model. We hypothesized that vascular oxidative stress and inflammation and changes in the immune response, including Treg activity and response, participate in the mechanisms leading to the metabolic syndrome.…”
mentioning
confidence: 99%
“…However, the underlying mechanisms remain controversial. Some studies report that adiponectin mRNA levels are increased after PPAR␥ agonist treatment but others do not (14,15). It is likely that PPAR␥ may exert its primary effect on adiponectin secretion by providing a more productive folding environment (2, 5) through transcriptional up-regulation of critical ER chaperones, including ERp44, Ero1-L␣ and DsbA-L, which may thus lead to a stimulation of assembly and release of the HMW form.…”
Section: Transcriptional Vs Posttranslational Roles Of Ppar␥ Activatmentioning
confidence: 99%